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Perchlorate is a powerful oxidant that is used
in rocket fuel, munitions, blasting operations,
and fireworks [National Research Council
(NRC) 2005]. Environmental contamination
has occurred at military installations, at facili-
ties that make perchlorate, and at various con-
struction sites from the blasting of bedrock to
build roads or homes. In addition, there are
natural sources of perchlorate such as fertilizer
produced in certain regions (e.g., Chilean
nitrate), evaporite soils, and atmospheric
sources (Dasgupta et al. 2005; Orris et al.
2003). Its high water solubility and environ-
mental persistence have led to contamination
of groundwater, with detection increasing in
recent years as analytical methods have
improved [Government Accountability Ofﬁce
(GAO) 2005]. There are no federal drinking
water standards for perchlorate, although a
number of states have recently developed or
proposed values in the 2–6 µg/L range
[Massachusetts Department of Environmental
Protection (MADEP) 2006; New Jersey
Drinking Water Quality Institute 2005;
Ting et al. 2006]. These drinking-water tar-
gets are intended to prevent perchlorate’s
neurodevelopmental effects resulting from its
antithyroid action. 
Perchlorate can impair thyroid function
by inhibiting the uptake of iodide, thereby
reducing the amount of iodide stored in the
thyroid and available for hormone produc-
tion (NRC 2005; Ting et al. 2006). In those
who have adequate iodide intake and stores of
thyroid hormone, this impairment can be
overcome with little to no consequence
(Braverman et al. 2005). However, gestation
can be a vulnerable period because the mother
has increased nutritional demands for iodide
and because thyroid hormone is critically
important for fetal brain development (NRC
2005). The U.S. Environmental Protection
Agency (EPA) reference dose (RfD) of 0.0007
mg/kg/day, as adopted from a report from the
National Research Council (NRC 2005; U.S.
EPA 2005), is intended to protect the general
public, including vulnerable life stages such as
in utero development, from perchlorate’s anti-
thyroid effects. This RfD has been used in at
least one case to derive a drinking-water limit
for perchlorate (New Jersey Drinking Water
Quality Institute 2005), whereas other states
have used more stringent toxicity values to set
a drinking-water limit (MADEP 2006; Ting
et al. 2006). The case for a lower RfD has also
been made by others (Ginsberg and Rice
2005). Recent data from the Centers for
Disease Control and Prevention (CDC) indi-
cate a low-dose effect of perchlorate, particu-
larly on women with low iodine intake, and
thus suggest a need to lower the RfD (Blount
et al. 2006a). 
In the present article we do not focus on
the issue of the appropriateness of the U.S.
EPA RfD, but rather evaluate whether a
groundwater cleanup guideline issued by U.S.
EPA’s Ofﬁce of Solid Waste and Emergency
Response (OSWER) would keep exposure
below the RfD for all vulnerable segments of
the population. The OSWER guideline,
released January 2006, sets a groundwater
preliminary remediation goal (PRG) of
24.5 µg/L for Superfund sites containing per-
chlorate. Whereas this level corresponds to
the amount that would deliver the RfD for a
70-kg adult ingesting 2 L/day, it is not neces-
sarily protective of nursing and bottle-fed
infants who consume more liquid per body
weight than adults (U.S. EPA 2002). A recent
analysis calculated perchlorate doses that were
above the RfD for infants drinking reconsti-
tuted formula made with water containing
perchlorate at 24 µg/L, the OSWER PRG
(Baier-Anderson et al. 2006). Further, from a
limited breast milk biomonitoring data set,
Kirk et al. (2005) estimated that nursing
infants could receive doses above the RfD
even without considering the added exposure
associated with the OSWER PRG. 
Our primary objective is to evaluate the
perchlorate dose to nursing infants resulting
from maternal ingestion of water contami-
nated by perchlorate at the OSWER PRG of
24.5 µg/L. As explained below and described
elsewhere (Baier-Anderson et al. 2006), infants
are likely also to be highly susceptible to per-
chlorate. The OSWER PRG did not explicitly
consider exposure during this life stage.
An additional objective is to evaluate
whether the OSWER PRG protects the preg-
nant mother and her developing fetus.
Exposure to the fetus depends on the
mother’s intake of perchlorate from both diet
and drinking water. In setting drinking-water
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BACKGROUND: Perchlorate is a common contaminant of drinking water and food. It competes with
iodide for uptake into the thyroid, thus interfering with thyroid hormone production. The U.S.
Environmental Protection Agency’s Ofﬁce of Solid Waste and Emergency Response (OSWER) set
a groundwater preliminary remediation goal (PRG) of 24.5 µg/L to prevent exposure of pregnant
women that would affect the fetus. This does not account for the greater exposure that is possible
in nursing infants or for the relative source contribution (RSC), a factor normally used to lower the
PRG due to nonwater exposures. 
OBJECTIVES: Our goal was to assess whether the OSWER PRG protects infants against exposures
from breast-feeding, and to evaluate the perchlorate RSC. 
METHODS: We used Monte Carlo analysis to simulate nursing infant exposures associated with the
OSWER PRG when combined with background perchlorate. 
RESULTS: The PRG can lead to a 7-fold increase in breast milk concentration, causing 90% of nurs-
ing infants to exceed the reference dose (RfD) (average exceedance, 2.8-fold). Drinking-water per-
chlorate must be < 6.9 µg/L to keep the median, and < 1.3 µg/L to keep the 90th-percentile nursing
infant exposure below the RfD. This is 3.6- to 19-fold below the PRG. Analysis of biomonitoring
data suggests an RSC of 0.7 for pregnant women and of 0.2 for nursing infants. Recent data from
the Centers for Disease Control and Prevention (CDC) suggest that the RfD itself needs to be
reevaluated because of hormonal effects in the general population. 
CONCLUSIONS: The OSWER PRG for perchlorate can be improved by considering infant expo-
sures, by incorporating an RSC, and by being responsive to any changes in the RfD resulting from
the new CDC data. 
KEY WORDS: drinking water, neurodevelopment, nursing infants, perchlorate, PRG, thyroid hormone.
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[Online 11 December 2006]maximum contaminant levels (MCLs), the
U.S. EPA routinely applies a relative source
contribution (RSC) to allow for the possibil-
ity that not all exposure will come from
water, recognizing the importance of keeping
the total exposure dose (e.g., water plus diet)
below the RfD. The default RSC is 0.2,
meaning that only 20% of the RfD would be
allowed to come from drinking water. In the
case of the OSWER PRG for perchlorate, the
groundwater target is set at the water concen-
tration that corresponds to the RfD—in
effect, setting the RSC to unity. This appears
to be contrary to the emerging database on
perchlorate content of foods, which shows
that perchlorate is common in the diet [El
Aribi et al. 2006; U.S. Food and Drug
Administration (FDA) 2004]. The limited
human biomonitoring data suggest wide-
spread exposure, with dietary perchlorate
appearing to be a key source (Kirk et al. 2005;
Valentin-Blasini et al. 2005). This indicates a
need for careful consideration of the RSC.
We provide a means to do this by analyzing
the available human biomonitoring data. 
Some may be less concerned about
exceedance of the RfD because it is based on a
precursor effect, inhibition of iodide uptake by
the thyroid. This implies that the RfD pre-
vents a biochemical change that precedes a
more serious toxic effect, and thus is not itself
a critical health end point. This assumption
lacks support; there are no data that show how
much iodide uptake inhibition is needed to
affect thyroid function. This relationship is
likely to depend on a number of host-speciﬁc
factors. For example, recent observations by
Blount et al. (2006a) demonstrate that women
in the lowest category of iodine intake were
most sensitive to perchlorate’s effects on thy-
roid hormone production. Analogous to the
low iodine women in the Blount et al. study
(2006a), neonates are likely to be a sensitive
life stage because of perchlorate’s direct effects
on the thyroid and its ability to limit iodine
transfer into breast milk, thereby reducing
infant intake of this nutrient (Kirk et al. 2005;
Tellez et al. 2005). Moreover, the simultane-
ous exposure to other breast milk contami-
nants (e.g., polychlorinated biphenyls,
polybrominated diphenyl ethers, dioxins) that
can disrupt thyroid function by other modes
of action may interact with perchlorate in
infants. Therefore, limiting perchlorate expo-
sure should be a critical public health target
not only during pregnancy but also in infants.
This rationale is further described below. 
Literature Review: Why Focus
on Perchlorate Effects in
Infants?
If the perchlorate mechanism of action is not
relevant to the postnatal period, or if this
period is considerably less sensitive than the
in utero period, then application of the RfD
to this period would be inappropriate.
Therefore, this analysis begins with a litera-
ture review describing factors that may affect
susceptibility to perchlorate during the post-
natal period. Because there is no indication
that the perchlorate mechanism of action
should differ across life stages, our review
focuses on the ability of neonates to compen-
sate for perchlorate-induced decreases in thy-
roid hormone synthesis. 
Sensitivity of newborns to thyroid disrup-
tion and altered brain development. During
the in utero period, the fetal brain undergoes
critical developmental stages that are supported
by the maternal supply of thyroid hormone T4
(thyroxine) (Howdeshell 2002). Maternal T4 is
an important source of thyroid hormone for
the fetus throughout gestation. It is the only
source during the ﬁrst trimester (Howdeshell
2002; Morreale de Escobar 2001), and remains
an important complement during late gesta-
tion, when it contributes approximately 30%
to the fetal supply of T4 (Vulsma et al. 1989) 
The importance of maternal T4 has been
demonstrated in babies with congenital
hypothyroidism who appear normal at birth
because of ample maternal hormone during
gestation (Vulsma et al. 1989). In contrast to
the fetus, the newborn can no longer rely on
maternal hormone as a buffer against inborn
biosynthetic deﬁciencies or external stressors.
The only means for hormone transfer from
the mother is breast milk; however, breast
milk contains very little thyroid hormone
(van Wassenaer et al. 2002). Therefore, the
neonate must synthesize its own supply of T4
to maintain normal growth and development.
As described below, several factors make
neonatal thyroid status more vulnerable to
perturbation than in adults or the fetus. 
First, the serum half-life of T4 is approxi-
mately 7–10 days in adults (Chopra and
Sabatino 2000), but is approximately 3 days in
neonates (Lewander et al. 1989; van den Hove
et al. 1999). Thus, the rate of replacement of
T4 (i.e., T4 secretion from the thyroid gland)
must be considerably higher in early life to
maintain steady-state levels. Second, the adult
thyroid gland stores a large quantity of thyroid
hormone in the form of thyroglobulin; this
quantity is estimated to be enough to main-
tain normal levels of circulating hormone for
several months (Greer et al. 2002). In con-
trast, the neonatal gland stores very little T4;
the amount stored has been estimated at less
than that required for a single day (Savin et al.
2003; van den Hove et al. 1999). These differ-
ences indicate that the functional reserve avail-
able to adults is virtually absent in neonates.
Any reduction in thyroid hormone synthesis
in the neonate will result in a reduction in cir-
culating levels, whereas this is clearly not true
for the adult. The combined storage deﬁciency
and rapid hormone turnover in neonates
necessitates a high rate of T4 synthesis to keep
up with the daily demand for thyroid hor-
mone. This, in turn, depends on an adequate
supply of iodide. Given these demands on the
neonatal thyroid, it is likely that perchlorate-
induced inhibition of iodide uptake has a
greater impact in neonates than in utero or at
other life stages. This is consistent with a
recent study of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) in rats that showed that post-
natal (lactational) exposure produced greater
thyroid disruption than exposure during the
in utero period (Nishimura et al. 2005).
Although rats have a different developmental
time frame than humans, and TCDD’s
mechanism of thyroid disruption differs from
that of perchlorate, the rat ﬁndings suggest an
important postnatal window of vulnerability
to thyroid toxicants. The concern for post-
natal effects is magnified with perchlorate
because of its potential to also interfere with
iodide excretion into breast milk. 
Considering these factors, it is critical to
understand the degree to which iodide uptake
must be inhibited in neonates to cause a reduc-
tion in thyroid hormone synthesis. However,
this relationship has not been explored in
neonates and is not well understood in adults.
The National Research Council perchlorate
report (NRC 2005) provided the following
estimate: “To cause declines in thyroid hor-
mone production that would have adverse
health effects, iodide uptake would most likely
have to be reduced by at least 75% for months
or longer.” However, to our knowledge, no
human or animal data exist that directly sup-
port this estimate. Epidemiologic studies in
regions of mild deﬁciency provide indirect esti-
mates of the degree to which iodide must be
reduced before adverse consequences occur.
Specifically, these studies show that iodine
intake that is 40–50% of that recommended
by the World Health Organization is associ-
ated with adverse consequences in infants and
children, including lower IQ and an increased
incidence of attention deﬁcit disorder (Aghini
Lombardi et al. 1995; Vermiglio et al. 2004).
These authors speculate that this association is
caused by thyroid hormone insufﬁciency sec-
ondary to moderately low iodine intake.
Although the relationship between perchlorate-
induced iodide uptake inhibition and thyroid
function is still poorly understood, it is likely
that the degree of inhibition required to affect
hormone status is < 75%. This conclusion is
supported by the recent observation that uri-
nary perchlorate levels that are commonplace
in the general population are associated with
changes in thyroid hormone levels in U.S.
women (Blount et al. 2006a). 
Insight into the sensitivity of neonates to
thyroid hormone insufﬁciency is perhaps best
documented in studies of infants with
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see Zoeller and Rovet 2004). These studies are
particularly useful because subjects are under
continuous medical surveillance, so there is
good documentation of the relationship
between endogenous thyroid hormone, levels
of hormone supplementation, and develop-
mental outcome (Heyerdahl and Oerbeck
2003). The neuropsychological outcome of
children diagnosed with CH at birth is associ-
ated with both the severity of CH and early
treatment factors (how soon T4 was adminis-
tered, starting dose and serum T4 levels during
the ﬁrst 2 years of life). These T4 parameters
were highly correlated with verbal IQ at 20
years of age, and children with CH who ulti-
mately completed high school had a signifi-
cantly higher T4 starting dose than those who
did not (Oerbeck et al. 2003). Interestingly,
the difference in mean starting dose between
these two groups was only 2.1 µg/kg/day.
Because iodine represents 65% (weight/weight)
of T4, the amount of iodine associated with
that T4 difference is only 1.37 µg/kg/day.
Others have found that a difference in starting
dose of only 12.5 µg/day (8.13 µg/day iodine
equivalent or 2.3 µg/kg/day) was associated
with a signiﬁcant difference in full-scale IQ of
11 points (Selva et al. 2002, 2005). Thus,
small differences in available thyroid hormone
(and the iodine associated with it) during the
ﬁrst few weeks of life can have signiﬁcant life-
time consequences.
These increased demands for thyroid hor-
mone production in neonates may be com-
pounded because adaptive mechanisms are not
as robust. These mechanisms may include
negative feedback responses [i.e., thyroid-stim-
ulating hormone (TSH) response to low T4],
changes in serum binding proteins or iodothy-
ronine transporters, or changes in deiodinases
(Zoeller 2005). Thus, a variety of adaptive
mechanisms available to adults may not be
available to the neonate, causing the neonate
to adapt poorly to iodide uptake inhibition.
Studies in rats indicate that the ability of the
neonate to adapt to low iodide is poor, that
compensation appears to be tissue-specific,
and that humans are likely to respond in a
similar manner (Pedraza et al. 2006). Mild
iodide deﬁciency lowered T4 in the absence of
an increase in TSH, suggesting that TSH may
not be a sensitive index of thyroid hormone
status in early life (Pedraza et al. 2006).
In summary, the data needed to perform
quantitative risk assessment for perchlorate in
neonates are limited. However, there is ample
reason to expect the neonatal period to be
highly sensitive to perchlorate-induced iodide
uptake inhibition. The neonate receives very
little thyroid hormone from breast milk and
so must depend on the function of its own
thyroid gland in the absence of stored 
hormone. Further, it is confronted with more
rapid hormone turnover. This situation is
compounded by the vulnerability of brain
development to even small deﬁcits in thyroid
hormone levels during this period. Impairment
of iodide uptake by perchlorate has been
described as a precursor effect in adults, largely
because of stored hormone and homeostatic
mechanisms that can compensate for the 
perchlorate-induced biochemical perturbation
(NRC 2005). The recent CDC data suggest
that there may be many women in whom
these compensatory mechanisms are inade-
quate even at background levels of perchlorate
(Blount et al. 2006a). The consequences in
neonates may be more signiﬁcant and lead to
long-term risks for neurocognitive deﬁcits. 
Lack of epidemiologic studies that assess
perchlorate effects in breast-fed infants. Several
studies have addressed the association between
perchlorate levels in drinking water and thy-
roid status of the neonate or child (Brechner
et al. 2000; Bufﬂer et al. 2006; Crump et al.
2000; Kelsh et al. 2003; Lamm 2003; Lamm
and Doemland 1999; Li et al. 2000a, 2000b;
Schwartz 2001; Tellez et al. 2005). Most of
these studies have failed to find an adverse
relationship, although there are a few excep-
tions. Interpretation of this body of evidence is
difficult because the studies suffer from the
fact that they were of ecologic design, and
because no information is provided on an
exposure route of primary concern to
neonates, breast-feeding. Regarding limita-
tions due to ecologic design, the levels of per-
chlorate actually consumed were not known in
any of the studies. This has the potential to
bias results toward the null, especially in the
case of perchlorate, given its prevalence in the
diet (El Aribi et al. 2006; FDA 2004). This
leads to the potential for exposure misclassiﬁ-
cation because studies typically categorized
exposure simply on the basis of perchlorate
levels in a common water supply. This limita-
tion applies to infant exposures that come
from breast milk and to post-weaning expo-
sures where perchlorate can come from the
child’s diet and drinking water. Although it
would not affect studies involving bottle-fed
infants during the ﬁrst months of life, we are
not aware of any studies that have speciﬁcally
evaluated this category of receptor.
None of the studies addressed the expo-
sure under consideration in the present analy-
sis: exposure to the nursing infant through
breast milk. In any of the studies it is likely
that some infants were breast-fed and others
were not. Without this speciﬁed, one cannot
analyze the relationship between nursing expo-
sure to perchlorate and thyroid status. Several
studies performed in the western United States
examined the association between perchlorate
in drinking water and neonatal thyroid hor-
mones (Brechner et al. 2000; Buffler et al.
2006; Kelsh et al. 2003; Lamm 2003; Lamm
and Doemland 1999; Li et al. 2000a, 2000b;
Schwartz 2001). This includes three studies
that followed infants past the neonatal period:
Li et al. (2000a) examined TSH levels at 2–7
and 8–30 days of age in a small subset of chil-
dren with low T4 levels; Li et al. (2000b)
examined T4 levels in infants as a function of
age from day 1 to 60 examined cross-section-
ally based on residence in Reno, Nevada (no
perchlorate in drinking water), compared with
Las Vegas, Nevada (perchlorate in drinking
water); and Brechner et al. (2000) examined
TSH levels between 0 and 132 days of age in
Yuma, Arizona (with perchlorate in the drink-
ing water), versus Flagstaff, Arizona (no per-
chlorate). The Li et al. studies (2000a, 2000b)
did not find an association with perchlorate
exposure, whereas the Brechner et al. study
(2000) did. Aside from limitations of ecologic
design and lack of information on nursing
exposure, these studies were limited in other
respects. For example, Li et al. (2000a) meas-
ured TSH in only a small fraction of infants
for whom T4 levels were at the low end of the
distribution, thereby examining a subsample
of infants that was not representative of the
population. Additionally, TSH levels were
treated as a dichotomous variable based on a
deﬁnition of clinical disease, even though lev-
els were available for analysis as a continuous
variable. The Li et al. (2000b) study of infants
out to 2 months of life suggests that levels of
perchlorate of up to 15 µg/L in Las Vegas did
not affect T4 levels. However, the Las Vegas
drinking-water perchlorate levels fluctuated
widely during this time, so it is difficult to
draw conclusions about perchlorate exposure
based on city of residence. The Brechner et al.
(2000) study has been questioned on the
grounds that Flagstaff represents an inappro-
priate reference location because of its much
higher elevation (Lamm 2003).
The series of studies in Chile (Crump
et al. 2000; Tellez et al. 2005) were the most
detailed but shared the deﬁciencies and incon-
sistencies described above for the U.S. studies.
Although neonates and ﬁrst- and second-grade
schoolchildren were evaluated, there were no
measurements during infancy and no infor-
mation on breast-feeding exposure. We ana-
lyzed these studies as ecologic studies even
though biomonitoring data were available in
one case (Tellez et al. 2005). However, the
biomonitoring data were not used to test
associations between perchlorate and hor-
mone status or goiter. There was no evidence
for a perchlorate-related difference in TSH,
triiodothyronine (T3), or T4, based on city of
residence, but the incidence of goiter in chil-
dren was greater in the two cities with the
higher levels of perchlorate in water. For the
history of thyroid disease in the family, the
high-perchlorate city (Taltal) had a signiﬁcant
increase compared with the reference city
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monitoring data from the Chilean study is
described further in “Methods Used in
Current Analysis.” As pointed out below, the
high iodide intake in these Chilean cities may
have affected the outcome of their study.
Overall, the epidemiologic studies do not
provide a body of evidence for determining
whether perchlorate will affect thyroid status or
neurodevelopment in infants. Therefore, the
mechanistic and developmental information
described in other sections of this article are
critical in evaluating whether the postnatal
period is likely to be vulnerable to perchlorate. 
Toxicokinetic considerations in the
neonate. Perchlorate is cleared unchanged in
the urine although protein binding can retain
perchlorate in serum and retard its excretion
(Clewell et al. 2003; Yu et al. 2002).
Biomonitoring studies have capitalized on
this excretory pathway because urinary per-
chlorate is an excellent biomarker for the gen-
eral public (Blount et al. 2006c). However,
there are no data on the efﬁciency of perchlo-
rate excretion in early life stages in humans
and only limited data in rats. In general,
human infants have immature renal function
and less urinary clearance of many water solu-
ble chemicals (Ginsberg et al. 2002; Kearns
and Reed 1989; Morselli 1989). This suggests
that slower clearance may be another factor
for increased vulnerability to perchlorate.
However, data from pre-weanling rats suggest
the opposite; rat pups had a higher perchlo-
rate dose than their mothers, but had lower
serum concentrations (Clewell et al. 2003;
NRC 2005, Appendix E). 
The rat data are of questionable relevance
to human infants, given the variety of cross-
species differences in the ontogeny of toxico-
kinetic systems (Ginsberg et al. 2004).
Regarding perchlorate, cross-species extrapola-
tion of chemical fate is affected by apparent
differences in plasma protein binding and
renal clearance between rats and adult humans
as simulated in well-calibrated toxicokinetic
models (Clewell et al. 2003; Merrill et al.
2005). The relevance of the neonatal rat data
(Clewell et al. 2003) to human infant dosime-
try is also affected by the fact that a) rat dams
drink nearly all of the urine excreted by their
pups, which inflates the serum level of per-
chlorate relative to the pup; and b) lactating
dams and pups were dosed with radioactive
iodide, which may affect perchlorate toxico-
kinetics, especially with regard to competition
for serum-binding sites. Another uncertainty
is the manner in which iodine intake may
affect perchlorate toxicokinetics and how this
may differ across species and life stages. These
uncertainties prevent one from drawing con-
clusions on the role of perchlorate toxico-
kinetics to affect dosimetry and risk in human
infants.
Added risk factor: potential lowering of
breast-milk iodide. An additional reason to
highlight nursing infants as a vulnerable popu-
lation is that perchlorate risks may be magni-
fied in this group by causing a concomitant
decrease in breast-milk iodide levels. The
sodium iodide symporter that is expressed in
the thyroid gland is also expressed in lactating
mammary gland. It transports iodide into
breast milk, with perchlorate able to take
iodide’s place and be selectively pumped into
breast milk (Clewell et al. 2003). This can lead
to exposure to perchlorate in nursing infants,
while at the same time leading to lower levels
of iodide in breast milk. This has been
demonstrated in rats where perchlorate expo-
sure to nursing dams resulted in decreased lev-
els of iodide in milk (Clewell et al. 2003). It is
expected that this effect on breast-milk iodide
will be modiﬁed by variations in dietary iodine
intake. However, the interaction between per-
chlorate and iodine ingestion on breast-milk
content of iodide has not been studied in rats
or humans. Perchlorate may also impair
iodine excretion into breast milk in humans,
as suggested by data showing an inverse corre-
lation between perchlorate and iodide concen-
trations in breast milk in a small number of
U.S. samples that were > 10 µg/L perchlorate
(Kirk et al. 2005). Tellez et al. (2005) did not
see a correlation, inverse or otherwise, between
perchlorate and iodide concentrations in
breast milk across three Chilean cities with
widely differing concentrations of perchlorate
in drinking water. However, there does seem
to be a factor that depresses iodide levels in
breast milk in these Chilean cities relative to
the United States. On average, Chilean breast-
milk iodide concentrations were 40% lower
than in U.S. women despite the fact that
iodide intake rates are known to be higher in
these Chilean cities than in the United States
(Kirk et al. 2005; Tellez et al. 2005). The fac-
tor responsible for lower-than-expected breast-
milk iodide levels in Chile may be that
baseline (dietary) exposure to perchlorate is
approximately three times higher in Chile
than in the United States (Valentin-Blasini
et al. 2005). 
The reason the Chilean cross-sectional
study did not find an inverse correlation
between breast-milk levels of perchlorate and
iodide is unclear, but comparisons were per-
formed only on the basis of group mean
(Tellez et al. 2005). Regression analysis of the
entire data set would be a more sensitive
method to determine whether there is a sig-
nificant relationship between these breast-
milk parameters in Chile. Further, the greater
intake of iodide in Chile may have amelio-
rated the perchlorate effect on breast-milk
iodide. Overall, the potential for perchlorate
intake by lactating women to lower the iodide
content of breast milk provides additional
rationale to consider this life stage to be of
prime concern for human risk assessment and
standard setting. 
Methods Used in Current
Analysis
Calculations of infant exposure to perchlorate
involve either ﬁxed inputs, generally the cen-
tral tendency value, or inputs that take the
form of a distribution of values. Monte Carlo
simulation analyses are used to present the
variability distributions for nursing exposure
under baseline conditions (dietary perchlorate
only) and with the added exposure associated
with the OSWER groundwater cleanup target
of 24.5 µg/L. The overall exposure equation is:
Nursing infant dose (µg/kg/day) =
(BMperc/UpercSF) × [(baseline Uperc) +
(added Uperc)] × (L breast milk 
ingested/day/infant body weight), [1]
where BMperc/UpercSF is the breast milk 
perchlorate-to-urinary perchlorate slope factor
(micrograms per liter per micrograms per
gram creatinine) as derived from the Chilean
study (Tellez et al. 2005). Baseline Uperc is the
baseline perchlorate excretion in the United
States from diet (no drinking water exposure)
(micrograms perchlorate/grams creatinine)
taken from the National Health and
Nutrition Examination Survey (NHANES)
2001–2002 biomonitoring data for 15- to
44-year-old women (Blount et al. 2006c). As
described below, this is included in Monte
Carlo simulations as a lognormal distribution.
Added Uperc is the increase in urinary perchlo-
rate (micrograms per gram creatinine) from
tap water ingestion at the OSWER ground-
water PRG of 24.5 µg/L. This was calculated
as follows: 
Uperc = (24.5 µg perchlorate/L water) ×
(L water ingested/day) ×
(1/1.165 g creatinine/day), [2]
where liters of water ingested by lactating
women was entered as a normal distribution
with a mean ± SD of 1.189 ± 699 L/day
(U.S. EPA 2002); and grams creatinine excre-
tion per day was based on data from 10
women of child-bearing age (Lentner 1981). 
L breast milk ingested-day/infant body
weight is the neonate consumption rate esti-
mated at 2 weeks of age to capture the average
over the ﬁrst month of life; input as a normal
distribution with mean 171.8 ± 26.46
mL/kg/day (U.S. EPA 2002). 
The following sections provide additional
details on the parameters needed to calculate
infant exposure to perchlorate via breast milk. 
Relationship between urinary and breast-
milk perchlorate (BMperc/UpercSF). Urinary
perchlorate is a reasonable index of the rate
of perchlorate intake under conditions of 
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which pseudo-steady state toxicokinetics are
achieved. The biomonitored populations in
Chile are exposed on a daily basis to perchlo-
rate in the diet and drinking water, so it is
reasonable to assume that their blood concen-
tration is relatively stable and approaching
steady state. The urinary concentration-to-
intake dose interconversion is facilitated by
the fact that excretion of unchanged parent
compound is the main means of elimination.
Three different Chilean cities were studied
which had a wide range of perchlorate expo-
sure via drinking water, as shown in Table 1
(Tellez et al. 2005). This table also shows the
urinary and breast-milk perchlorate data for
these cities. The breast-milk statistics for
Antofagasta do not include one outlier subject
who had very high breast-milk perchlorate
(1,042 µg/L). 
We used linear regression to relate the
mean concentrations of perchlorate in breast
milk to urine across the three cities. The
regression line was weighted by the inverse of
the variance in the data for each city. The line
was forced through the origin because it can
be expected that with zero intake by the
mother (and thus no perchlorate in urine),
there should also be none in breast milk. The
size of the sampled groups differed consider-
ably between the urinary and breast-milk
measurements (Table 1). The lack of paired
measurements from the same individuals pre-
cludes a more precise analysis of the correla-
tion between these parameters. 
Baseline urinary perchlorate concentra-
tion in the U.S. population without drinking
water exposure (baseline Uperc). We assessed
urinary perchlorate concentrations based on a
randomized sample (n = 2,818) intended to
be representative of the U.S. general popula-
tion ≥ 6 years of age, as part of the NHANES
2001–2002 biomonitoring campaign (Blount
et al. 2006c). This is a large expansion on the
earlier perchlorate biomonitoring data set
published by the CDC from a convenience
sample of 61 adult residents of Atlanta,
Georgia (Valentin-Blasini et al. 2005). The
larger data set includes results for 662
women, 15–44 years of age. This subsample
was selected as the baseline population to
evaluate nursing exposures. Although a base-
line population of nursing mothers would
have been ideal, NHANES did not obtain a
sizeable or representative sample from this
group. The urinary data for the sample of 662
women as well as the urine biomonitoring
data from the Chilean cities appear to be log-
normally distributed as evidenced by the ﬁt of
the data to regression lines in log probability
plots for each city (Figure 1) (for background
on probability plots, see Hattis and Burmaster
1994). Therefore, dietary perchlorate intake
inferred from urinary perchlorate data from
Atlanta were input as a log-normal distribu-
tion to represent baseline perchlorate exposure
for Monte Carlo analysis. 
The group sampled by NHANES is
assumed to represent baseline perchlorate
exposure that comes from the diet without a
substantial contribution from drinking water.
NHANES did not obtain drinking-water per-
chlorate data. However, a small pilot study
conducted by the CDC measured urinary
perchlorate in conjunction with drinking-
water perchlorate and dietary factors for 27
subjects in Atlanta (Blount et al. 2006b).
Drinking-water perchlorate averaged only
0.11 µg/L (range < 0.05–0.25 µg/L) for these
27 individuals, a small contribution given
that these subjects were excreting approxi-
mately 5 µg perchlorate/day. The importance
of diet in determining urinary perchlorate was
shown by dividing the group into those who
ate one or fewer versus three or more servings
of dairy or leafy green vegetables. The higher
servings group had an average urinary per-
chlorate that was 1.8-fold higher. Figure 2
shows urinary perchlorate for all 27 Atlanta
subjects compared with the 662 women sam-
pled by the NHANES 2001–2002. The log
probability plot shows a reasonable corre-
spondence between these data sets. The
Atlanta sample had a higher median but the
two populations converged at the upper end
of the distribution. Because the Atlanta
distribution was not materially affected by
drinking-water intake, Figure 2 suggests that
the NHANES distribution, even at the upper
end, is what can be expected from diet alone.
Therefore, we considered the NHANES uri-
nary perchlorate distribution for these women
as a reasonable baseline for projecting the
added impact of drinking water at the
OSWER PRG. 
We modeled the contribution of maternal
water ingestion to urinary perchlorate by
combining the expected perchlorate exposure
associated with a normal distribution of daily
water consumption with the log-normal dis-
tribution of baseline urinary perchlorate.
Correction was made for creatinine excretion
rate per day as described above. These equa-
tions also assume that perchlorate ingested
per day is equal to perchlorate urinary excre-
tion per day under pseudo-steady state condi-
tions. The Monte Carlo simulations were
done in triplicate runs of 5,000 trials each.
Results
Evaluation of the impact of the OSWER
groundwater PRG on exposures and risks to
nursing infants. The relationship between per-
chlorate exposure, as estimated from urinary
perchlorate excretion, and perchlorate in
breast milk is shown in Figure 3 across the
Evaluation of perchlorate PRG
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Table 1. Biomonitoring results (mean ± SD) for three Chilean cities. 
Antofagasta Chanaral Taltal
Tap water perchlorate (µg/L) ND (< 4) 5.82 ± 0.63 114 ± 13.3
Urinary perchlorate (µg/g creatinine) 28.4 ± 22 80.2 ± 129.6 135.5 ± 95
No. 61 53 59
Breast-milk perchlorate (µg/L) 7.7 ± 7.5a 18.3 ± 17.7 95.6 ± 54.6
No. 13 16 25
Data adapted from Tellez et al. (2005). ND, not detected.
aThe Antofagasta breast-milk data reﬂect one less sample than reported by Tellez et al. (2005) due to an outlier in this group.
The mean was recalculated by multiplying the original mean (81.6 µg/L) by the original no. (14), subtracting the outlier
(1,042 µg/L) and then dividing by the new no. (13). Variability in this group was assumed to be on a par with that in Chanaral.
Figure 1. Log-normal probability plots of the distrib-
utions of urinary perchlorate excretion in three
Chilean cities and the United States. Taltal: y = 2.03
+ 0.306x; R2 = 0.984. Chanaral: y = 1.66 + 0.304x; R2 =
0.968. Antofagasta: y = 1.31 + 0.326x; R2 = 0.962.
NHANES: y =0.50 + 0.332x; R2 = 0.997.
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Figure 2. Comparison of urinary perchlorate (µg/g
creatinine) between Atlanta sample of 27 adults
versus national sample of women 15–44 years of
age. Atlanta: y = 0.622 + 0.258x; R2 = 0.974. NHANES:
y = 0.498 + 0.332x; R2 = 0.997.
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ethree Chilean cities. This is the only data set
that provides both parameters for the same
population. The regression line for these three
cities (weighted by inverse variance of the
mean of each datapoint) provides a slope of
0.387 (micrograms per liter breast milk per
micrograms per gram creatinine). The line is
less influenced by the Taltal results than by
the other data points because of the large
uncertainty in the mean breast-milk concen-
tration for the Taltal data. 
We used this slope to convert urinary per-
chlorate to breast-milk perchlorate for the base-
line U.S. population distribution as derived
from the 668 women sampled by NHANES.
The distribution of breast-milk perchlorate in
this baseline population is shown in Figure 4,
which has a simulated mean ± SD of 1.63 ±
1.5 µg/L. The vast majority of the baseline
population (> 90%) would be expected to have
measureable perchlorate in breast milk at a
detection limit of 0.4 µg/L (detection limit
from Kirk et al. 2005). This agrees with the
high rate of detection seen in the limited
breast-milk data currently available (Kirk et al.
2005). Figure 4 also shows the total perchlo-
rate in breast milk after adding to the baseline a
daily tap water exposure of 24.5 µg/L (the
OSWER PRG). The distribution is shifted
approximately 7-fold to the right with a new
mean ± SD of 11.45 ± 5.7. The 99th per-
centile value is 25.2 µg/L. 
We then used these breast-milk concen-
trations to simulate nursing exposure in
infants within the ﬁrst month of life, as repre-
sented by the intake rate per body weight for
2-week-old infants. The resulting exposure
dose for both the baseline and (+) OSWER
(an added 24.5 µg/L in drinking water) sce-
narios is presented in Figure 5. The two dis-
tributions are quite distinct, with the
log-normal baseline distribution overlapping
only about 30% of the (+) drinking water dis-
tribution. Figure 5 also shows the U.S.
EPA/Integrated Risk Information System
(IRIS) RfD (0.7 µg/kg/day). The RfD is sur-
passed at approximately the 95th percentile of
the baseline population and at the 15th per-
centile of the (+) drinking water distribution.
The average nursing infant exposure dose for
the baseline population is 40% of the RfD,
whereas the average for the (+) 24.5 µg/L
drinking-water scenario is 2.8-fold greater
than the RfD. The 95th percentile of the (+)
drinking-water distribution exceeds the RfD
by 5.4-fold. These results suggest that perchlo-
rate exposure associated with the OSWER
PRG, in conjunction with background dietary
exposure, results in exposures to nursing
infants in excess of the RfD for the great
majority (85%) of the population. In fact, the
upper end of the baseline distribution is also
above the RfD.
Table 2 shows the baseline distribution of
nursing infant exposure as projected from the
NHANES data set, along with the perchlo-
rate drinking-water targets that would satisfy
the RfD at different percentiles of the distrib-
ution. Adherence to the RfD would require a
groundwater cleanup level of 6.9 µg/L for the
50th percentile of the baseline distribution,
and 1.3 µg/L at the 90th percentile. 
Evaluation of the RSC needed to protect in
utero development and nursing infants. A key
consideration in setting the PRG is whether
an RSC term is needed to protect sensitive life
stages (in utero, postnatal) and what the value
should be. This depends on the extent of non-
drinking-water exposure to perchlorate relative
to the perchlorate RfD. In this section we use
the NHANES data for 668 women to provide
an indication of dietary contribution to per-
chlorate exposure for RSC consideration. 
Table 3 shows the daily exposure dose in
adults implied by the urinary excretion data
from NHANES (Blount et al. 2006c). When
central estimates from the NHANES study are
considered, dietary exposure appears to consti-
tute approximately 10% of the RfD. At the
95th percentile, diet is still only 32% of the
RfD, which would support an RSC of 0.7 in
the case of pregnant women. This is consider-
ably larger than the default RSC of 0.2 com-
monly used in drinking-water risk assessments. 
These estimates pertain to adult baseline
(dietary) exposure as a percentage of the RfD.
Review of Figure 5 indicates that baseline
exposure of nursing infants is 40% of the
RfD for average exposure and it exceeds the
RfD at the 95th percentile. Therefore, base-
line dietary exposure of the mother produces
a nursing infant–based RSC in the range of
0.6 (average case) to 0 (no allowance for
drinking water exposure). This latter estimate
of the nursing infant–based RSC is obtained
because the RfD is exceeded at the 95th per-
centile of exposure in the maternal diet-to-
breast-milk-to-nursing infant pathway. 
Discussion 
The OSWER PRG is an important guidance
for the Superfund program in that it establishes
the initial groundwater target that, if surpassed,
would attract the attention of site managers
and health officials. It is not necessarily the
ﬁnal cleanup level because it can be increased
or decreased based on site-speciﬁc considera-
tions. The factors presented in this article have
little to do with site-speciﬁc features but rather
Ginsberg et al.
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Figure 3. Mean (± SD) breast-milk perchlorate con-
centration in relation to mean urine perchlorate
excretion. Data adapted from Tellez et al. (2005).
Inverse invariance-weighted straight line con-
strained to pass through the origin.
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Figure 4. Simulated cumulative distribution of
breast-milk concentrations for baseline and
OSWER PRG scenarios.
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Figure 5. Daily doses from nursing infant exposure
to perchlorate under baseline and (+) drinking
water scenarios. 
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Table 2. Drinking-water targets for different per-
centiles of the perchlorate exposure distribution.a
Baseline nursing  Drinking-water target 
infant exposure  (µg/L) to maintain 
Percentile (µg/kg/day) infant at RfD
0.5 0.028 > 24.5
1 0.034 > 24.5
2 0.042 > 24.5
5 0.058 > 24.5
10 0.076 > 24.5
25 0.122 12.4
50 0.206 6.9
75 0.347 3.8
90 0.562 1.3
95 0.744 —b
aBaseline distribution is that derived for the NHANES data
set. This is overlaid with the distribution of maternal expo-
sure to perchlorate and transfer to nursing infant. bThere
is no drinking-water concentration that can satisfy this
condition because the baseline exposure is already above
the RfD for a nursing infant.address exposure and toxicity issues relevant to
all sites where there is potential for groundwa-
ter ingestion by pregnant women, nursing
mothers, and infants. The higher dose rate
received by nursing infants and the contribu-
tion of diet to total perchlorate dose are key
considerations, and represent an opportunity
for improving the scope and public health pro-
tectiveness of the PRG. 
Our literature review and analysis indicate
that there are toxicodynamic and toxicokinetic
reasons to consider early postnatal life as a
particularly vulnerable time for perchlorate
toxicity. Further, this life stage has not been
adequately assessed in perchlorate epidemiol-
ogy studies. This is a critical issue because, as
suggested elsewhere (Baier-Anderson et al.
2006; Kirk et al. 2005) and as presented in
this article, infants can have greater perchlo-
rate exposure than people at other life stages
from ingestion of reconstituted formula or
breast milk. This provides an imperative to
evaluate nursing infants in risk assessments of
perchlorate in drinking water. 
In the current analysis we incorporate data
on urinary and breast-milk perchlorate con-
centrations into a Monte Carlo analysis of the
distribution of intake of perchlorate by nurs-
ing infants at the OSWER PRG. Our simula-
tions indicate that 85% of nursing infants can
be expected to exceed the RfD, with the aver-
age exceedance 2.8-fold. In fact, the perchlo-
rate drinking-water concentration needs to be
< 6.9 µg/L to keep the 50th percentile nursing
infant below the RfD. The corresponding
value for the 90th percentile infant is
1.3 µg/L. These drinking-water concentrations
are 4- to 19-fold below the OSWER PRG and
are more in line with proposals for regulating
perchlorate in groundwater in a number of
states (MADEP 2006; New Jersey Drinking
Water Quality Institute 2005; Ting et al.
2006). Ideally, one would develop a perchlo-
rate groundwater target that keeps 95% of
nursing infants below the RfD, but this would
require a target of < 1 µg/L. Comparison of
Tables 2 and 3 shows that perchlorate doses
are expected to be approximately 3-fold higher
in nursing infants than in adult women. 
Use of biomonitoring data to evaluate the
RSC in adult women found that dietary per-
chlorate likely represents 32% of the RfD
when considering the 95th percentile of the
NHANES distribution. This corresponds to
an RSC of 0.7, which is somewhat higher
than the RSC applied by the California EPA
(0.6) (Ting et al. 2006). However, the RSC
would be in the range of 0.6 to 0 when con-
sidering the baseline exposure of nursing
infants from mother’s diet-only intake of per-
chlorate. Thus, protection of nursing infants
from perchlorate would require an RSC at
least as low as the default often used in setting
drinking-water standards—0.2. The lack of
an RSC in OSWER’s PRG derivation in
effect assumes that 100% of the daily perchlo-
rate exposure comes from drinking water,
omitting the contribution from diet. Thus,
there is considerable room for reevaluation of
the PRG. The RSC estimate is based on a
particular RfD. Obviously, if the RfD were
lower, then the baseline (dietary) exposure
would constitute a larger fraction, necessitat-
ing a decrease in the RSC. For example, using
benchmark dose analysis from the Greer et al.
(2002) data set, the California EPA derived a
perchlorate toxicity point of departure that is
approximately 2-fold lower than that used in
the IRIS RfD (Ting et al. 2006). Based on
this toxicity value, the RSC estimate would
need to be cut in half. Further, recent evi-
dence from the same NHANES/CDC data
set described above indicates an effect on thy-
roid hormone status in adult women at per-
chlorate intake levels that are below the RfD
(Blount et al. 2006a). Table 3 shows the aver-
age intake of women in the NHANES study
to be approximately 10-fold below the IRIS
RfD. This is likely in the range of perchlorate
effect levels, given that Blount et al. (2006a)
found the thyroid hormone effect along a
continuous function with perchlorate dose
that spanned the center of the exposure distri-
bution. Therefore, future evaluations of the
RSC will need to take into account any
changes in the RfD that may occur as the
human dose-response is reanalyzed. 
Uncertainties. The current analysis requires
knowledge of baseline exposure to perchlorate
via nondrinking water sources, primarily the
diet. The recent biomonitoring data set devel-
oped as part of NHANES 2001–2002 (Blount
et al. 2006c) provides a very useful starting
point for estimating the population distribu-
tion of dietary perchlorate intake. The compar-
ison against biomonitoring results from 27
Atlanta residents who had minimal perchlorate
in their tap water (Figure 2) indicates that the
NHANES distribution is likely a reasonable
estimation of background (dietary) exposure.
What is less certain is the conversion of the uri-
nary biomonitoring level to intake dose for
these subjects. This is a key starting point for
perchlorate risk assessment. The central
assumption is that the amount of perchlorate
excreted per day equals the amount ingested in
the biomonitored individuals. This is true if
these individuals are near or at steady state. In
such cases the daily exposure can be viewed as a
maintenance dose which keeps body stores at a
relatively constant level i.e., no net accumula-
tion or loss. This occurs in people whose expo-
sure rate is fairly uniform, a situation that can
be expected for perchlorate because it is present
in a variety of foods (El Aribi et al. 2006; FDA
2004). This approach for relating urinary bio-
monitoring data and intake rate has also been
used for other chemicals at or near steady state,
such as phthalates (Koch et al. 2003; Kohn
et al. 2000; Koo et al. 2002) and chlorpyrifos
(Rigas et al. 2001). 
A caveat with this application of biomoni-
toring data is that it depends on urinary excre-
tion data normalized per gram of creatinine,
which is multiplied by the creatinine excretion
rate per day to yield the daily perchlorate
excretion rate. However, the creatinine excre-
tion rate per day is not typically measured in
individual subjects; rather, a central popula-
tion estimate is used, as in the present analysis.
This does not account for the considerable
interindividual variability in creatinine excre-
tion as seen in an analysis of NHANES III
data (Barr et al. 2005). This source of variabil-
ity is not expected to bias the analysis in a par-
ticular direction, but could be incorporated
into future Monte Carlo analyses by including
the creatinine excretion rate as a distribution
rather than a ﬁxed central estimate. 
It is useful to contrast estimates of perchlo-
rate dietary ingestion in the NHANES data
set with those developed elsewhere. Data from
the three Chilean cities suggest that dietary
perchlorate is consistent across the three 
cities, 20–35 µg/day on average, or 0.3–0.5
µg/kg/day (Tellez et al. 2005). This is approxi-
mately 5-fold above the average intake rate we
calculated for 15- to 44-year-old women
sampled by NHANES—0.075 µg/kg/day
(Table 3). This is consistent with there being
higher perchlorate in soil, fertilizer, and locally
grown foods in Chile than in the United States
(Crump et al. 2000; El Aribi et al. 2006). 
Another area of uncertainty is the conver-
sion of biomonitored levels of perchlorate in
urine to breast milk perchlorate. We used the
only available data set that provides both uri-
nary and breast-milk biomonitoring data, the
Chilean data from three cities (Tellez et al.
2005). The strength of this data set is that it
captures a wide range of perchlorate exposures.
However, the number of subjects for which
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Table 3. Percentage of the IRIS RfD taken up by non-drinking-water sources in 15- to 44-year-old women
sampled in NHANES 2001–2002.a
NHANES sample Urinary output (µg/g creatinine) Maternal dose (µg/kg/day)b Percent RfDc
50thpercentile 2.97 0.056 8
Average 4.0 0.75 11 
90th percentile 8.4 0.16 23
95th percentile 12.1 0.23 32
aUrinary perchlorate data adapted from Blount et al. (2006c). bConverted from perchlorate in urine based on daily creati-
nine excretion of 1.165 g and adult female body weight of 62 kg. cIRIS RfD established in 2005 is 0.7 µg/kg/day.Ginsberg et al.
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breast-milk data were available is considerably
smaller than the number of subjects for which
urinary data were available. The lack of pair-
matched results meant that the correlation
could be determined only on a population
mean basis, relying on only three data points,
one for each city, rather than the individual
data points. Although the line in Figure 3 rep-
resents a reasonable best fit across the three
cities, a more robust and comprehensive
analysis would have been possible if individ-
ual, pair-matched data were available. 
A potentially greater uncertainty in using
the Chilean data to represent the urinary-to-
breast-milk relationship is that this relation-
ship may be different in the United States.
Although iodide supplementation in these
Chilean cities has decreased in recent years,
iodine intake in Chile still appears to be
higher than in the United States (Tellez et al.
2005). This may affect, via substrate competi-
tion, the distribution of perchlorate into vari-
ous compartments into which it is actively
transported. Just as high perchlorate impairs
iodide excretion into breast milk, it is also
possible that high iodide decreases perchlorate
entry into breast milk. This would cause a
shallower breast-milk-to-urinary-perchlorate
slope in Figure 3 and underpredict nursing
infant exposures in the United States. That
this may be the case is presented in Figure 6,
which compares breast-milk perchlorate
simulated from the NHANES data with
actual data from Kirk et al. (2005). The
actual data were collected from 36 women
across 18 states in the United States. Both
distributions appear log-normal with the bulk
of the results < 10 µg/L. However, the Kirk
et al. (2005) distribution is shifted to the right
of the NHANES-based simulation (Kirk et al.
median = 3.3 µg/L; NHANES simulation
median = 1.2), and there are numerous high-
end individuals in the Kirk et al. data set not
predicted by the simulation. The higher per-
chlorate levels in the Kirk et al. data set may
be caused by greater perchlorate intake from
the diet or drinking water than in the
NHANES subjects, although there is no rea-
son to think that the Kirk et al. population
was biased toward high-exposure individuals.
A distinct possibility is that the slope between
breast-milk and urinary perchlorate is greater
in the United States than in Chile, causing
our simulations of nursing exposure and risk
to be an underestimate. This would also lower
the OSWER groundwater PRG needed to
keep nursing infants below the current RfD.
More studies are needed that deﬁne perchlo-
rate levels in U.S. breast milk and that explore
the interaction between iodide and perchlo-
rate at the mammary symporter. 
Conclusions
The neonate may be particularly vulnerable to
perchlorate toxicity because of a number of fac-
tors described in this article. This means that
the OSWER PRG of 24.5 µg/L should be
evaluated in light of neonatal exposures.
Baseline exposure as simulated from NHANES
biomonitoring data takes up a substantial frac-
tion of the RfD in nursing infants, which does
not allow much additional perchlorate expo-
sure from drinking water. In this regard, the
OSWER PRG could result in perchlorate
exposures that exceed the RfD in a high per-
centage of nursing infants. This is generally
true for pregnant women because an RSC was
not used in OSWER’s PRG calculation.
Proposed drinking-water standards set for
perchlorate by several states (New Jersey,
Massachusetts, California) are in the range of
2–6 µg/L, well below the OSWER PRG. We
recommend that OSWER reevaluate the per-
chlorate PRG in light of the early-life exposure
and RSC factors raised here. In addition.
recent data from the CDC on perchlorate’s
effects on thyroid status in adult women
(Blount et al. 2006a) need to spur follow-up
studies and become incorporated into future
perchlorate risk assessments. 
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